Adherence, insight and disability in paranoid schizophrenia
| Autor: | Covadonga M. Díaz-Caneja, M. Ovejero, E. de Portugal, Ignacio Garcia-Cabeza |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Paranoid schizophrenia Treatment adherence Pharmacological treatment 03 medical and health sciences 0302 clinical medicine mental disorders Humans Medicine In patient Biological Psychiatry Schizophrenia Paranoid Positive and Negative Syndrome Scale business.industry Awareness Middle Aged medicine.disease 030227 psychiatry Psychiatry and Mental health Schizophrenia Patient Compliance Female Schizophrenic Psychology business 030217 neurology & neurosurgery Psychopathology Clinical psychology |
| Zdroj: | Psychiatry Research. 270:274-280 |
| ISSN: | 0165-1781 |
| DOI: | 10.1016/j.psychres.2018.09.021 |
| Popis: | Insight has long been linked to both prognosis and functioning in patients with schizophrenia; likewise, it is key to treatment adherence. This study seeks to assess the association between insight, adherence to pharmacological treatment, and disability in schizophrenia, and to study the potential mediating role of adherence between insight and disability. Insight (SUMD), adherence (CRS), and disability (WHO-DAS) were measured in 80 clinically stable patients with DSM-IV TR paranoid schizophrenia. Psychopathology was assessed with the Positive and Negative Syndrome Scale (PANSS). In a first step, predictors of disability were identified using linear regression to identify variables related to disability and further a mediation analysis was carried out. Negative symptoms, insight, and adherence account for 54.2% of the variance in disability. Negative symptoms act directly on disability, while the effect of insight on disability is partially mediated by adherence. Insight is key in disability in schizophrenia and should be leveraged in treatment programs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect